24870-10-8

Basic information

• Product Name: N-(4-METHOXYPHENYL)MALEAMIC ACID
• Synonyms: ASISCHEM Z49471;AKOS AUF0561;OTAVA-BB BB7010590147;N-(P-METHOXYPHENYL)MALEAMIC ACID;N-(4-METHOXYPHENYL)MALEAMIC ACID;Maleic acid mono(4-methoxyphenyl)amide;(Z)-4-(4-Methoxyphenylamino)-4-oxo-2-butenoic acid;(Z)-4-Oxo-4-[(4-methoxyphenyl)amino]-2-butenoic acid
• CAS NO: 24870-10-8
• Molecular Formula: C₁₁H₁₁NO₄
• Molecular Weight: 221.21
• Mol File: 24870-10-8.mol
• Article Data: 53

Chemical Properties

• Boiling Point: 473°C at 760 mmHg
• Flash Point: 239.9°C
• Appearance: /
• Density: 1.318g/cm³
• Vapor Pressure: 9.4E-10mmHg at 25°C
• Refractive Index: 1.609
• CAS DataBase Reference: N-(4-METHOXYPHENYL)MALEAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-METHOXYPHENYL)MALEAMIC ACID(24870-10-8)
• EPA Substance Registry System: N-(4-METHOXYPHENYL)MALEAMIC ACID(24870-10-8)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 24870-10-8(Hazardous Substances Data)

Usage

General Description

N-(4-methoxyphenyl)maleamic acid is a chemical compound with the molecular formula C11H11NO5. It is a derivative of maleic acid and contains a 4-methoxyphenyl group. N-(4-METHOXYPHENYL)MALEAMIC ACID has been studied for its potential pharmaceutical and industrial applications, including as a building block for the synthesis of biologically active compounds and as a reactant in organic synthesis. It has also been investigated for its potential role in the development of new materials and polymers. N-(4-methoxyphenyl)maleamic acid may have potential as a versatile and valuable compound for use in various chemical and biological processes.

InChI:InChI=1/C11H11NO4/c1-16-9-4-2-8(3-5-9)12-10(13)6-7-11(14)15/h2-7H,1H3,(H,12,13)(H,14,15)/b7-6-

Upstream product

• 108-31-6 maleic anhydride 
• 783-08-4 [4-(benzylideneamino)phenyl]methanol 
• 108-88-3 toluene 
• 104-94-9 4-methoxy-aniline 
• 112634-26-1 N-ethyliden-p-anisidine 

Downstream Products

• 1081-17-0 N-(4-methoxyphenyl)maleimide 
• 36342-13-9 3-chloro-1-(4-methoxyphenyl)succinimide 
• 59653-00-8 6β-[3-(4-methoxy-phenylcarbamoyl)-acryloylamino]-penicillanic acid 
• 65344-77-6 2-Decylsulfanyl-N-(4-methoxy-phenyl)-succinamic acid 
• 80167-51-7 (Z)-3-(4-Methoxy-phenylcarbamoyl)-acrylic acid methyl ester 
• 51229-34-6 N-p-methoxy-phenylisomaleimide 
• 106691-38-7 N-(4-Methoxy-phenyl)-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-acetamide 
• 19990-24-0 5-[N-(4-methoxyphenyl)-imino]-5H-furan-2-one 
• 80167-56-2 (E)-methyl-3-(4-methoxyphenylcarbamoyl)acrylate 
• 2314-80-9 2-(4-methoxyphenyl)succinimide 
• 58684-79-0 2-(4-Methoxyphenyl)-5,6-dimethyl-3a,4,7,7a-tetrahydroisoindole-1,3-dione 
• 37910-34-2 3-(4-ethoxy-anilino)-1-(4-methoxy-phenyl)-pyrrolidine-2,5-dione 
• 37034-97-2 3-(4-methoxy-anilino)-1-(4-methoxy-phenyl)-pyrrolidine-2,5-dione 
• 106058-52-0 1-(4-Methoxy-phenyl)-3-(4-phenylsulfanyl-phenylamino)-pyrrolidine-2,5-dione 

Relevant articles and documents

Organotin(IV) derivatives of amide-based carboxylates: Synthesis, spectroscopic characterization, single crystal studies and antimicrobial, antioxidant, cytotoxic, anti-leishmanial, hemolytic, noncancerous, anticancer activities

Four new triorganotin(IV) amide based carboxylates of general formula R3SnL1 and R3SnL2, where R = Me(1,3) and n-butyl (2,4), and L1= (Z)-4-(p-methoxyphenylamino)-4-oxo-2-butenoic acid (HL1

Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments

"Hot loop" protein segments have variable structure and conformation and contribute crucially to protein-protein interactions. We describe a new hot loop mimicking modality, termed PepNats, in which natural product (NP)-inspired structures are incorporated as conformation-determining and-restricting structural elements into macrocyclic hot loop-derived peptides. Macrocyclic PepNats representing hot loops of inducible nitric oxide synthase (iNOS) and human agouti-related protein (AGRP) were synthesized on solid support employing macrocyclization by imine formation and subsequent stereoselective 1,3-dipolar cycloaddition as key steps. PepNats derived from the iNOS DINNN hot loop and the AGRP RFF hot spot sequence yielded novel and potent ligands of the SPRY domain-containing SOCS box protein 2 (SPSB2) that binds to iNOS, and selective ligands for AGRP-binding melanocortin (MC) receptors. NP-inspired fragment absolute configuration determines the conformation of the peptide part responsible for binding. These results demonstrate that combination of NP-inspired scaffolds with peptidic epitopes enables identification of novel hot loop mimics with conformationally constrained and biologically relevant structure.

Design, synthesis and biological evaluation of novel 3,4-dihydro-2(1H)-quinolinone derivatives as potential chitin synthase inhibitors and antifungal agents

A series of 3,4-dihydro-2(1H)-quinolinone derivatives contained butenediamide fragment were designed and synthesized. Their inhibition potency against chitin synthase and antimicrobial activities were screened in vitro. The enzymatic assays showed that all the synthesized compounds had inhibition potency against chitin synthase at concentration of 300 μg/mL. Compound 2d displayed excellent potency with inhibition percentage (IP) value of 82.3%, while IP value of the control polyoxin B was 87.5%. Compounds 2b, 2e and 2s whose IP values were above 70% showed good inhibition potency against chitin synthase. Moreover, the IC50 value of 2b was comparable with that of polyoxin B (0.09 mM). The Ki of compound 2b was 0.12 mM and the result from Lineweaver-Burk plot showed that 2b was non-competitive inhibitor to bind chitin synthase. The antifungal experiment showed that these compounds had excellent antifungal activity against fungal strains, especially for candida albicans. The antifungal activities against C .albicans of compounds 2b, 2d, 2e and 2l were comparable with that of fluconazole and were superior to that of polyoxin B. Meanwhile, the other compounds against C. albicans showed better antifungal activity (MIC 2 μg/mL) than polyoxin B except for compound 2n (MIC 4 μg/mL). The trial of drug combination use showed that these synthesized compounds had synergistic effects with fluconazole and polyoxin B. It indicated that these compounds were not competing with polyoxin B to bind with chitin synthase, which was also consistence with the result of enzymatic assays. The antibacterial experiment showed that these compounds had no activity against selected strains including three Gram-positive and three Gram-negative bacteria. These results showed that the designed compounds were chitin synthase inhibitors and had selective antifungal activity.